Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062010 · ClinicalTrials.gov registry record · Phase 2
Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00062010 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 37 participants.
The verdict
NCT00062010, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Giving interferon alfa and isotretinoin together with paclitaxel may reduce resistance to the drug and allow the tumor cells to be killed. PURPOSE: This phase II trial is studying how well giving interferon alfa and isotretinoin together with paclitaxel works in treating patients with recurrent small cell lung cancer.
Interventions
- DRUG 13-cis-retinoic acid
- DRUG paclitaxel
- BIOLOGICAL interferon alpha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2004-05-26 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062010
The ClinicalTrials.gov registry entry for NCT00062010 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 13-cis-retinoic acid is the first listed.
NCT00062010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062010 about?
NCT00062010 is a clinical study titled "Interferon Alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Some tumors become resistant to chemotherapy drugs. Giving interferon alfa and isotretinoin together with paclitaxel may reduce resistance to the drug and ...
What is the current status of trial NCT00062010?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2004-05-26. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00062010?
The interventions under investigation include: 13-cis-retinoic acid (DRUG), paclitaxel (DRUG), interferon alpha (BIOLOGICAL).
Who is sponsoring clinical trial NCT00062010?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.